A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma

BACKGROUND: Preclinical data suggest some cannabinoids may exert antitumour effects against glioblastoma (GBM). Safety and preliminary efficacy of nabiximols oromucosal cannabinoid spray plus dose-intense temozolomide (DIT) was evaluated in patients with first recurrence of GBM. METHODS: Part 1 was...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Br J Cancer
Autori principali: Twelves, Chris, Sabel, Michael, Checketts, Daniel, Miller, Sharon, Tayo, Bola, Jove, Maria, Brazil, Lucy, Short, Susan C.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group UK 2021
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8039032/
https://ncbi.nlm.nih.gov/pubmed/33623076
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-021-01259-3
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi